Line 32: |
Line 32: |
| ==== Increase Myocardial Systolic Function ==== | | ==== Increase Myocardial Systolic Function ==== |
| | | |
− | This helps with dilated cardiomyopathy and [[Mitral Valve Dysplasia|mitral valve disease]] (dog & cat) but is '''contraindicated''' in animals with [[Hypertrophic Cardiomyopathy|hypertrophic cardiomyopathy]] (dog & cat). '''Positive Inotropes''' can be used to stimulates myocardial contractility to improve cardiac output regardless of preload. This class of drug includes digitalis compounds (e.g. Digoxin, Digitoxin), calcium sensitisers/ phosphodiesterase III. inhibitor (e.g. Pimobendan), pure phosphodiesterase inhibitors (e.g. Milrinone, Amrinone) and catecholamines (e.g. Dobutamine, Dopamine). | + | This helps with dilated cardiomyopathy and [[Degenerative Mitral Valve Disease|mitral valve disease]] (dog & cat) but is '''contraindicated''' in animals with [[Hypertrophic Cardiomyopathy|hypertrophic cardiomyopathy]] (dog & cat). '''Positive Inotropes''' can be used to stimulates myocardial contractility to improve cardiac output regardless of preload. This class of drug includes digitalis compounds (e.g. Digoxin, Digitoxin), calcium sensitisers/ phosphodiesterase III. inhibitor (e.g. Pimobendan), pure phosphodiesterase inhibitors (e.g. Milrinone, Amrinone) and catecholamines (e.g. Dobutamine, Dopamine). |
| | | |
| The disadvantage of positive inotropes is that increased myocardial work causes increased myocardial oxygen demand. | | The disadvantage of positive inotropes is that increased myocardial work causes increased myocardial oxygen demand. |
Line 40: |
Line 40: |
| This helps with hypertrophic cardiomyopathy and myocardial fibrosis where ventricular filling is compromised. Drugs include the beta blockers (e.g. Atenolol, Propranolol) and calcium channel blockers (e.g. Diltiazem). | | This helps with hypertrophic cardiomyopathy and myocardial fibrosis where ventricular filling is compromised. Drugs include the beta blockers (e.g. Atenolol, Propranolol) and calcium channel blockers (e.g. Diltiazem). |
| | | |
| + | |
| + | {{Chapter}} |
| + | {{Mansonchapter |
| + | |chapterlink = http://www.mansonpublishing.co.uk/book-images/9781840761856_sample.pdf |
| + | |chaptername = Congestive Heart Failure in the Dog (part of Congestive Heart Failure in the Cat) |
| + | |book = Small Animal Emergency and Critical Care Medicine |
| + | |author = Elizabeth Rozanski, John Rush |
| + | |isbn = 9781840761856 |
| + | }} |
| | | |
| == References == | | == References == |
Line 59: |
Line 68: |
| | | |
| [[Category:Expert_Review]] [[Category:Heart_Failure]] | | [[Category:Expert_Review]] [[Category:Heart_Failure]] |
| + | [[Category:Cardiology Section]] |